Infectious Disease

Recurrent Urinary Tract Infections

26

Pipeline Programs↗

5

Active Trials↗

7

Companies Involved↗

Recurrent urinary tract infections is an emerging landscape with 26 programs across 7 companies. The most active players are Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, Alnylam Pharmaceuticals, Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). 10 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

51/100

Pipeline Velocity

6/100

Mech. Concentration

29/100

Completion Rate

73/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

1 program

Alnylam Pharmaceuticals

1 program

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

1 program

Meitheal

1 program

Mylan Pharmaceuticals Inc

1 program

Novo Nordisk

2 programs

Pipeline

Programs by Phase

Preclinical8

Amikacin

Insmed Incorporated

Ciprofloxacin

Bayer

Uromune

Queen's University

E. Coli 83972

Region Skane

MV-140

Unidade Local de Saúde Santa Maria

Phase 12

Nitrofurantoin

Procter and Gamble

Saccharomyces Boulardii

Biocodex

Phase 23

Cranberry Juice

National Center for Complementary and Integrative Health (NCCIH)

Immunization With Inactivated Bacteria

University of Wisconsin, Madison

Intravesical Heparin

University of Oklahoma

Phase 33

Estradiol

Novo Nordisk

Trimethoprim/sulfamethoxazole

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Prasterone

Alnylam Pharmaceuticals

Approved10

Ertapenem

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Ceftazidime

Philadelphia Eye Associates

Meropenem

B. Braun Medical Inc.

Fosfomycin

Meitheal

Vagifem

Novo Nordisk

Analysis

Trial Status

24

clinical trials

Completed11 · 46%

Unknown status3 · 13%

Terminated3 · 13%

Recruiting2 · 8%

Active, not recruiting2 · 8%

No longer available1 · 4%

Other2 · 8%

Clinical Trials

Trial Activity

24 trials

Faecal Microbiota Transplantation as Means of Preventing Recurrent Urinary Tract Infections

Recruiting·HHelsinki University Central Hospital·Phase 2/3·NCT06050148·100 enrolled

Alternative Prophylaxis in Female Recurrent Urinary Tract Infections

Recruiting·UUniversity Hospital, Basel, Switzerland·Phase 4·NCT04095572·50 enrolled

MV-140 Efficacy in Recurrent Urinary Tract Infections in a Cohort of Portuguese Adult Patients

Active, not recruiting·UUnidade Local de Saúde Santa Maria·N/A·NCT06392282·104 enrolled

Adherence to Vaginal Estrogen Therapy in Hypoestrogenic Women With Recurrent Urinary Tract Infections

Active, not recruiting·UUniversity of California, Irvine·Phase 4·NCT06353269·111 enrolled

Daily Nitrofurantoin Versus Bladder Fulguration Plus Daily Nitrofurantoin for Women With Recurrent Urinary Tract Infections

Not yet recruiting·UUniversity of Texas Southwestern Medical Center·Phase 1·NCT06907199·104 enrolled

Efficacy and Safety of Fecal Microbiota Transfer (FMT) for Recurrent Urinary Tract Infections in Women

Completed·FFundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal·Phase 2·NCT07194941·40 enrolled

E. Coli 83972 Induced Asymptomatic Bacteriuria (ABU) in Patients With Recurrent Urinary Tract Infections (UTI)

Completed·—·N/A·NCT00927316·30 enrolled

Fecal Microbiota Transplantation for the Treatment of Recurrent Urinary Tract Infections

Completed·UUniversity of California, Irvine·Phase 1·NCT03050515·12 enrolled

D Mannose in Recurrent Urinary Tract Infections

Completed·FFondazione IRCCS Policlinico San Matteo di Pavia·Phase 3·NCT01808755·60 enrolled

Acupuncture for Prevention of Recurrent Urinary Tract Infections.

Completed·MMedical University of Graz·N/A·NCT02705495·136 enrolled

Efficacy of Collagen, Propolis Plus Quercetin (Proqutin®), Bacillus Coagulans, Hyaluronic Acid and Chondroitin Sulphate and D-Mannose to Avoid Symptoms and Prevents Recurrence in Women With Recurrent Urinary Tract Infections

Completed·UUniversity of Campania Luigi Vanvitelli·Phase 4·NCT06659016·148 enrolled

Periurethral vs Intravaginal Estrogen for Prevention of Recurrent Urinary Tract Infections

Completed·—·Phase 2·NCT05472779·114 enrolled

Examination of the Efficacy of Preventive Antibiotic Treatment During the Puerperium Among Pregnant Women With Recurrent Urinary Tract Infections

Completed·HHaEmek Medical Center, Israel·N/A·NCT01507974·220 enrolled

Cranberry Juice for the Prevention of Recurrent Urinary Tract Infections

Completed·NNational Center for Complementary and Integrative Health (NCCIH)·Phase 2·NCT00128128·176 enrolled

Vaccine for Recurrent Urinary Tract Infections in Women

Completed·UUniversity of Wisconsin, Madison·Phase 2·NCT00261248·75 enrolled

Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)